Lncap

Human prostate cancer cell lines LNCaP, VCaP, and 22Rv1 were purchased from ATCC (Manassas, VA, USA). LNCaP and 22Rv1cells were grown in RPMI 1640 medium (NISSUI, Tokyo, Japan) containing 10% FBS (MP Biomedicals, Strasbourg, France), 0.3 mg/ml glutamine. VCaP cells were grown in Dulbecco’s modified Eagle medium (NISSUI) containing 10% FBS (Sigma-Aldrich, St Louis, MO, USA).

Human colorectal adenocarcinoma-derived cell line LoVo, of which some loci were different from those of an original LoVo (ATCC: CCL-29), was kindly provided by Kirin corporation. Human colorectal adenocarcinoma-derived cell line HCT116, HT29, and DLD-1, human non-small cell lung cancer (NSCLC) adenocarcinoma-derived cell line A549, and human prostate cancer-derived cell line LNCaP were obtained from the American Type Culture Collection (ATCC, Rockville, MD, USA). LoVo, HCT116, HT29, DLD-1, and LNCaP cells were maintained in Roswell Park Memorial Institute (RPMI) medium 1640 (RPMI1640; Nissui Pharmaceutical, Tokyo, Japan) containing 10% fetal bovine serum (FBS; JRH Biosciences), 100 U/mL of penicillin G (Sigma #13752), and 0.1 mg/mL of kanamycin (Sigma #K1377). A549 cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM; Nissui Pharmaceutical) supplemented with 10% FBS, 100 U/mL of penicillin G, and 0.1 mg/mL of kanamycin. All cell lines were maintained at 37°C in a 5% CO₂–95% air atmosphere. Unfortunately, we conducted a study using Mycoplasma-infected cells in some experiments.